NEUROBO PHARMACEUTICALS INC (NRBO) Stock Income Statement
USA - NASDAQ:NRBO - US64132R4048 - Common Stock
2.36 USD
+0.01 (+0.43%)
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 28.89M | 15.89M | 11.42M | 15.30M | 12.38M | |||
| Research and Development | 21.36M | 9.16M | 2.78M | 6.55M | 4.53M | |||
| Selling, General, and Administrative Expenses | 7.53M | 6.73M | 8.64M | 8.75M | 7.85M | |||
| Operating Income | -28.89M | -15.89M | -11.42M | -15.30M | -12.38M | |||
| Interest Income/Expense | 1.01M | 461.00K | -2.19M | 10.00K | 40.00K | |||
| Other Income/Expense | 148.00K | 2.96M | 7.85M | 0 | 0 | |||
| Non Recurring Items | null | 0 | -8.21M | 0 | -17.34M | |||
| Income Before Taxes | -27.73M | -12.47M | -13.97M | -15.28M | -29.68M | |||
| Income Tax | null | 0 | 0 | 0 | 0 | |||
| Net Income | -27.73M | -12.47M | -13.97M | -15.28M | -29.68M | |||
| EBITDA | -28.87M | -15.88M | -11.40M | -15.25M | -12.33M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -4.7682400000000005 | -2.45903 | -5.43 | -19.84 | -54.96 | |||
| Non GAAP EPS | -6 | -3.9265600000000003 | null | null | -55.2 | |||
| Statistics | ||||||||
All data in USD